Flagship Pioneering-backed Profound Therapeutics Inc. made its debut with $75 million from its originator to support ongoing efforts with the Profoundry platform, which the company said has led to the discovery of tens of thousands of novel proteins as part of an ambitious plan for “remapping the landscape of the human genome.”